| Jul 15 |
Autonomix's Trial Results Show Meaningful Reduction In Pain For Patients Suffering From Pancreatic Cancer
|
| Jul 15 |
Autonomix Enters into Definitive Agreement to License Intellectual Property for FDA-Cleared Ablation Technology from RF Innovations, Inc.
|
| Jul 11 |
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Launch of CEO Corner Platform
|
| Jul 3 |
Autonomix Medical, Inc. (NASDAQ: AMIX) Reviews Positive Results Seen in Pancreatic Cancer Pain Trial in Virtual Investor “What This Means” Segment
|
| Jun 18 |
Autonomix Announces Positive Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial
|
| Jun 18 |
Autonomix appoints Brad Hauser as CEO
|
| Jun 17 |
Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer
|
| Jun 6 |
This One Company Is Working On A Breakthrough Approach To Revolutionize Pain Management
|
| Jun 3 |
Autonomix Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial
|
| May 23 |
Autonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer
|
